A 28-year-old man from Kolkata presents on day 6 of fever with severe abdominal pain, persistent vomiting, and a blood pressure of 95/65 mmHg with a narrow pulse pressure (30 mmHg). His platelet count is 45,000/μL, haematocrit 48% (baseline 42%), and AST 320 U/L. He had a confirmed dengue infection 8 months ago. What is the epidemiological significance of his current presentation, and what is the primary mechanism underlying his increased risk of severe dengue?

Explanation

## Epidemiological Significance and Pathophysiology of Secondary Dengue ### Clinical Diagnosis: Dengue Shock Syndrome (DSS) — Secondary Dengue **Key Point:** This patient meets WHO criteria for DSS: - Fever (day 6) - Thrombocytopenia (45,000/μL) - Plasma leakage (haematocrit rise from 42% to 48% = 14% rise, borderline; hypotension 95/65 with narrow pulse pressure 30 mmHg is diagnostic) - Haemorrhagic manifestations (persistent vomiting, abdominal pain) - Circulatory collapse (hypotension, narrow pulse pressure) The **prior dengue infection 8 months ago** is the critical epidemiological clue: this is a **secondary dengue infection** (re-infection with a different serotype). ### Antibody-Dependent Enhancement (ADE): The Primary Mechanism ```mermaid flowchart TD A[Primary dengue infection]:::outcome --> B[Serotype-specific antibodies develop] B --> C[8 months later: Re-infection with different serotype]:::outcome C --> D{Non-neutralizing antibodies bind new virus}:::decision D -->|ADE pathway| E[Antibody-virus complex enters macrophages via Fc receptors]:::action E --> F[Massive viral replication in immune cells]:::action F --> G[Cytokine storm: TNF-α, IL-6, IL-8]:::action G --> H[Increased vascular permeability, thrombocytopenia, coagulopathy]:::action H --> I[Plasma leakage, shock, haemorrhage]:::urgent D -->|No ADE| J[Controlled viral replication]:::outcome ``` **High-Yield:** ADE is the hallmark of secondary dengue. Non-neutralizing antibodies from the first infection bind the new serotype but do NOT neutralize it. Instead, the antibody-virus complex enters macrophages and dendritic cells via Fc receptors, leading to: 1. **Increased viral replication** (10–100 fold higher than primary infection) 2. **Enhanced immune activation** (massive cytokine release: TNF-α, IL-6, IL-8, IL-10) 3. **Endothelial dysfunction** (increased vascular permeability, plasma leakage) 4. **Thrombocytopenia and coagulopathy** (direct viral infection of megakaryocytes + immune-mediated destruction) ### Epidemiological Timeline | Timing | Event | Immune Status | Risk of Severe Dengue | |--------|-------|----------------|----------------------| | **0–8 months ago** | Primary dengue (serotype, e.g., DENV-1) | Serotype-specific IgG develops | Low | | **8 months ago to present** | Interval: no dengue | IgG wanes; IgM absent | Baseline | | **Day 0 (current)** | Secondary dengue (different serotype, e.g., DENV-2) | Non-neutralizing IgG + new IgM | **Very high (DHF/DSS risk 15–20%)** | **Clinical Pearl:** Secondary dengue carries a 15–20% risk of DHF/DSS, compared to < 1% for primary dengue. The critical window is **2–12 weeks after primary infection**, when IgG is high but IgM is absent; however, risk persists for years if re-infection occurs. ### Why Secondary Dengue is More Severe **Mnemonic: SHADE** — **S**econdary infection, **H**igher viral load, **A**ntibody enhancement, **D**amage (cytokines), **E**ndothelial leak. [cite:Park 26e Ch 8, Harrison 21e Ch 189]